1. Suppressed expression of Cbl‐b by NF‐κB mediates icotinib resistance in EGFR‐mutant non‐small‐cell lung cancer
   Tieqiong Zhang et al, 2019, Cell Biology International CrossRef
2. Downregulation of microRNA‑21 expression inhibits proliferation, and induces G1 arrest and apoptosis via the PTEN/AKT pathway in SKM‑1 cells
   Guang Li et al, 2018, Molecular Medicine Reports CrossRef
3. Hypoxia‑inducible factor-1 signaling pathway influences the sensitivity of HCC827 cells to gefitinib
   Qian Jin et al, 2019, Oncology Letters CrossRef
4. Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
   Junnan Li et al, 2020, Cancers CrossRef
5. MicroRNA‐92b acts as an oncogene by targeting PTEN/AKT in NSCLC
   Jia‐Hui Guo et al, 2020, Cell Biochemistry and Function CrossRef
6. PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
   H. Blons et al, 2021, Lung Cancer CrossRef
7. TPD7 inhibits the non-small cell lung cancer HCC827 cell growth by regulating EGFR signalling pathway
   Xiaoyan Zhang et al, 2022, Journal of Chemotherapy CrossRef
8. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
   Surya K. Tripathi et al, 2020, Medicinal Research Reviews CrossRef